OncoMatch/Clinical Trials/NCT06055621
Evaluation of DASATINIB Monotherapy Efficacy in Acute Myeloid Leukemia Patients Refractory to VENETOCLAX-AZACITIDINE
Is NCT06055621 recruiting? Yes, currently enrolling (Jun 2026). This Phase 2 trial studies Dasatinib for acute myeloid leukemia.
Treatment: Dasatinib — The goal of this clinical trial is to learn about the efficacy of DASATINIB monotherapy in acute myeloid leukemia patients refractory to VENETOCLAX-AZACITIDINE. The main question it aims to answer is to assess the tumor response after 2 cycles of DASATINIB monotherapy treatment for patients with chemotherapy-ineligible acute myeloid leukemia refractory to VENETOCLAX-AZACITIDINE therapy. Participants will be given DASATINIB treatment up to 3 months. Response will be assessed by a myelogram and a complete blood count at the end of every cycle. Follow up will last 6 months.
Check if I qualifyExtracted eligibility criteria
Treatments studied
Targeted therapy
Cancer type
Acute Myeloid Leukemia
Performance status
ECOG 0–3(Limited self-care)
Prior therapy
Must have received: VENETOCLAX-AZACITIDINE (venetoclax, azacitidine)
VEN-AZA refractory defined as no response after two cycles of VEN-AZA whatever the dose and the treatment duration
Cannot have received: targeted therapy having a market authorization
Patient eligible to a targeted therapy having a market authorization
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Frequently asked questions
Is NCT06055621 currently recruiting?
Yes, this trial is currently recruiting patients.
Are there prior therapy exclusions?
Yes. Prior targeted therapy having a market authorization disqualifies patients from enrollment.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualifyRelated pages